Jemperli

Dostarlimab, the active ingredient in Jemperli, is a monoclonal antibody presented as a lyophilized powder for solution for infusion for intravenous use. It treats dMMR/MSI‑H advanced or recurrent endometrial cancer in adult patients.

GNH USA supplies Jemperli as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

Jemperli is a PD‑1 inhibitor used in the management of cancers that exhibit deficient mismatch repair or high microsatellite instability.

- dMMR/MSI‑H advanced or recurrent endometrial cancer: improves disease control in patients whose tumors show these biomarkers. - Endometrial cancer (PD‑1 inhibitor therapy): provides an immunotherapy option for patients with specific molecular profiles. - Microsatellite instability‑high solid tumours (investigational): being evaluated in clinical studies for broader oncologic use.

Jemperli may cause a range of immune‑related adverse reactions.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: loose stools that may require supportive care. - Rash or pruritus: skin irritation or itching. - Infusion‑related reactions: transient fever, chills, or flushing during administration.

Serious or Rare Side Effects: - Immune‑mediated pneumonitis: inflammation of lung tissue that can be life‑threatening. - Colitis or hepatitis: severe inflammation of the colon or liver requiring immunosuppression. - Endocrinopathies: thyroiditis, adrenal insufficiency, or hypophysitis. - Severe infusion reactions: anaphylaxis or cardiovascular compromise. - Myocarditis: inflammation of heart muscle with potential cardiac dysfunction.

When using Jemperli, clinicians should observe several safety measures.

- Monitor for immune‑mediated adverse events: assess organ function regularly. - Manage infusion reactions: have emergency medications and monitoring equipment ready. - Avoid live vaccines: immunosuppression may reduce vaccine efficacy. - Pregnancy and breastfeeding: safety not established; weigh potential risks and benefits. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Jemperli can interact with other therapies that affect the immune system.

Major Interactions (Avoid): - Concurrent use with other PD‑1/PD‑L1 inhibitors: increased risk of severe immune toxicity. - Combination with systemic immunosuppressants: may diminish therapeutic efficacy. - Live vaccines: heightened risk of infection due to immune modulation.

Moderate Interactions (Monitor Closely): - Corticosteroids: may mask signs of immune‑related adverse events. - Anticoagulants: monitor for bleeding if thrombocytopenia develops. - Enzyme‑inducing drugs: no known pharmacokinetic effect but clinical response should be observed.